Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Bristol-Myers Squibb
The primary and secondary endpoints applied to sub-groups defined by age, race, diabetes, metabolic syndrome and prior HTN therapy.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient must have hypertension and uncontrolled SBP on monotherapy.
Patients who have read, signed and received a copy of the informed consent prior to any study procedures
Note: Female patients must be post-menopausal for one year, surgically sterilized, or using a medically accepted method of contraception (intrauterine device, oral contraceptives, barrier method with spermicide) and must agree to use an effective method of contraception throughout the study.
You may not be if
Any history of secondary hypertension
History of hypertensive encephalopathy, stroke, or transient ischemic attack (TIA) within the past 12 months
History of myocardial infarction, percutaneous transluminal coronary revascularization, coronary artery bypass graft, and/or unstable angina pectoris within the past 6 months
Clareo Health | The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension
